Cover Image
市場調查報告書

心絞痛治療藥市場分析與預測:藥品分級(乙型阻斷劑,鈣拮抗劑,硝酸鹽,抗凝固藥,ACE抑制劑,Ranolazine),各主要市場 2016年∼2022年

Angina Pectoris Drugs Market Analysis, By Therapeutic Class (Beta Blockers, Calcium Antagonists, Nitrates, Anticoagulants, ACE inhibitors, Ranolazine), By Major Markets, And Segment Forecasts, 2016 - 2022

出版商 Grand View Research, Inc. 商品編碼 600860
出版日期 內容資訊 英文 85 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
心絞痛治療藥市場分析與預測:藥品分級(乙型阻斷劑,鈣拮抗劑,硝酸鹽,抗凝固藥,ACE抑制劑,Ranolazine),各主要市場 2016年∼2022年 Angina Pectoris Drugs Market Analysis, By Therapeutic Class (Beta Blockers, Calcium Antagonists, Nitrates, Anticoagulants, ACE inhibitors, Ranolazine), By Major Markets, And Segment Forecasts, 2016 - 2022
出版日期: 2017年11月21日 內容資訊: 英文 85 Pages
簡介

慢性心絞痛的罹患率的資料,美國、英國、德國、法國、義大利、西班牙、日本等已開發國家為2.0%∼4.0%,性別、各年齡層從45歲到54歲的男性2.0%∼5.0%,從65歲到74歲的男性10.0%∼20.0%,從45歲到54歲的女性0.1%∼1.0%,從65歲到74歲的女性10.0%∼15.0%。心絞痛可藉由改善生活習慣來預防。全球心絞痛治療藥市場,預計2022年成長到106億美元。全球心絞痛治療藥市場,緩解疾病藥和標靶治療的需求增加,心絞痛的盛行率的增加,醫療支出的增加,有效的治療方法的確立等,進成長促。

本報告提供全球心絞痛治療藥市場相關調查,市場概要,各藥品分級、主要市場、地區的市場趨勢,市場規模的變化與預測,成長促進、阻礙因素分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 調查方法

  • 資訊採購
  • 資訊/資料分析

第2章 摘要整理

第3章 疾病的底層塗料與免疫學

  • 概要

第4章 全球市場概要

  • 概要
  • 市場分析:各藥品分級
  • 市場規模的變化與預測
  • 市場佔有率
  • 銷售額成果:各藥品分級
  • 領導品牌的市場趨勢
  • 專利到期分析
  • 市場促進、阻礙因素
  • M&A及交易情形
  • 生物相似藥的發展
  • 新興市場
  • 價格設定及回本方案
  • SWOT分析

第5章 開發平台資訊

  • 開發平台形勢
  • 開發平台預測

第6章 企業簡介

  • Chapter Summary
  • Sanofi
  • Gilead Sciences
  • AstraZeneca
  • Amgen
  • GlaxoSmithKline
  • Eli Lilly
  • Pfizer

第7章 市場預測

  • 市場未來展望
  • 勝者和敗者
  • 新興企業和新技術的平台
  • 市場預測
目錄
Product Code: GVR-2-68038-045-3

The global angina pectoris drugs market is expected to be valued at USD 10.6 Billion by 2022, as per a new report by Grand View Research, Inc. The global angina pectoris market is collectively driven by demand for disease-modifying and targeted treatments, increased expenditure on healthcare and availability of effective treatment methods across the emerging markets.

Additionally, the rising prevalence and incidence of angina pectoris is anticipated to fuel the market growth. Chronic stable angina pectoris has a prevalence of 2.0-4.0% in developed markets such as the U.S., the U.K., Germany, France, Italy, Spain and Japan. The prevalence of angina pectoris rises sharply with age in both genders, ranging from 2.0- 5.0% in men aged 45-54 to 10.0-20.0% in men aged 65-74, and from 0.1-1.0% in women aged 45-54 to 10.0-15.0% in women aged 65-74. The disease symptoms can be managed by following a healthy lifestyle.

Further key findings from the report suggest:

  • The U.S. dominated this space by accounting for more than 33.0% of the market share in 2016 due to increasing incidence of cardiac disorders and presence of key manufacturers in the U.S.
  • The angina pectoris drug market is commercially meaningful, however branded sales are in decline as generics dominate a larger portion of prescriptions. Though the market is fragmented, key players such as Sanofi, Gilead, AstraZeneca and Pfizer hold significant market positions
  • Biosimilar development is emerging as a promising market opportunity in angina pectoris therapeutics. Multiple biosimilars have gained approvals in the U.S., European and Indian markets
  • China offers strong opportunity for market expansion due to removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform and supportive 12th Five-Year Plan measure, which targets biotechnology as the key development sector
  • Changing regulatory scenario in the U.S. presents favorable environment for disruptive technologies in healthcare. In the EU, the new Clinical Trials Regulation (EU No. 536/2014) will impact clinical trials of Advanced Therapy Medicinal Products. Industry concerns regarding ROIs on novel therapies remains a challenge to drug development.
  • Some of the key players operating in this industry are Sanofi, Gilead, AstraZeneca, Pfizer, Eli Lilly, Amgen and GlaxoSmithKline

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1. Chapter Summary
    • 3.1.1 Disease Primer/101
    • 3.1.2 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU 5)

Chapter 4 Global Market Overview

  • 4.1 Chapter Summary
  • 4.2 Market, by Therapeutic Class
  • 4.3 Market Size and Forecast 2016 - 2022
  • 4.4 Market Share Distribution, by Company 2016 - 2022
  • 4.5 Sales Performance, by Drug Class
  • 4.6 Market Dynamics among Leading Brands
  • 4.7 Patent Expiry Analysis
  • 4.8 Angina Pectoris Market: Drivers and Restraints
    • 4.8.1 Drivers
    • 4.8.2 Challenges
  • 4.9 M&A, Deal Landscape (2013- 2017 YTD)
    • 4.9.1 Mergers & Acquisitions
    • 4.9.2 Deals Landscape
  • 4.10 Evolution of Biosimilars
  • 4.11 Emerging Markets
  • 4.12 Pricing and Reimbursement Scenario
  • 4.13 Angina Pectoris Sector SWOT

Chapter 5 Pipeline Intelligence

  • 5.1. Pipeline Landscape
    • 5.1.1 Leading Drugs in Development
    • 5.1.2 Key R&D Trends
  • 5.2 Pipeline Landscape
    • 5.2.1 Late Stage Pipeline and Sales Forecast
    • 5.2.2 Profiles of Disruptive Drugs
  • 5.3 Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1 Chapter Summary
  • 6.2 Sanofi
    • 6.2.1 Company Overview
    • 6.2.2 Current Product Portfolio
    • 6.2.3 Product Sales Forecast Through 2022
    • 6.2.4 Strategic Initiatives
      • 6.2.4.1 Key Company News Flow
      • 6.2.4.2 Catalysts & Events Calendar
    • 6.2.5 Pipeline Analysis & Overview
    • 6.2.6 SWOT
  • 6.3 Gilead Sciences
    • 6.3.1 Company Overview
    • 6.3.2 Current Product Portfolio
    • 6.3.3 Product Forecast Sales Through 2022
    • 6.3.4 Strategic Initiatives
      • 6.3.4.1 Key Company News Flow
    • 6.3.5 SWOT
  • 6.4 AstraZeneca
    • 6.4.1 Company Overview
    • 6.4.2 Current Product Portfolio
    • 6.4.3 Product Forecast Sales Through 2022
    • 6.4.4 Strategic Initiatives
      • 6.4.4.1 Key Company News Flow
      • 6.4.4.2 Catalysts & Events Calendar
    • 6.4.5 Pipeline Analysis & Overview
    • 6.4.6 SWOT
  • 6.5 Amgen
    • 6.5.1 Company Overview
    • 6.5.2 Current Product Portfolio
    • 6.5.3 Product Forecast Sales Through 2022
    • 6.5.4 Strategic Initiatives
      • 6.5.4.1 Key Company News Flow
      • 6.5.4.2 Catalysts & Events Calendar
    • 6.5.5 Pipeline Analysis & Overview
    • 6.5.6 SWOT
  • 6.6 GlaxoSmithKline
    • 6.6.1 Company Overview
    • 6.6.2 Current Product Portfolio
    • 6.6.3 Product Forecast Sales Through 2022
    • 6.6.4 Strategic Initiatives
      • 6.6.4.1 Key Company News Flow
    • 6.6.5 Pipeline Analysis & Overview
    • 6.6.6 SWOT
  • 6.7 Eli Lilly
    • 6.7.1 Company Overview
    • 6.7.2 Current Product Portfolio
    • 6.7.3 Product Forecast Sales Through 2022
    • 6.7.4 Strategic Initiatives
      • 6.7.4.1 Key Company News Flow
    • 6.7.5 SWOT
  • 6.8 Pfizer
    • 6.8.1 Company Overview
    • 6.8.2 Current Product Portfolio
    • 6.8.3 Product Forecast Sales Through 2022
    • 6.8.4 Strategic Initiatives
      • 6.8.4.1 Key Company News Flow
    • 6.8.5 Pipeline Analysis & Overview
    • 6.8.6 SWOT

Chapter 7 Market Outlook

  • 7.1 What the Future Holds
  • 7.2 The Winners and Losers
  • 7.3 Emerging Companies & New Technology Platforms
  • 7.4 The Road Ahead

List of Tables

  • TABLE 1 Stable Angina Pectoris Total Estimated Prevalence Rate in Top Seven Markets
  • TABLE 2 U.S. Patents for Current Angina Pectoris Drugs
  • TABLE 3 Average Cost of CAD Treatment in Patients With and Without Angina Pectoris
  • TABLE 4 Table Number and Cost of Prescriptions for Angina Pectoris in the UK
  • TABLE 5 R&D Pipeline Overview
  • TABLE 6 Late Stage Pipeline
  • TABLE 7 Pipeline Forecast
  • TABLE 8 Off Patent Products in Angina Pectoris Market
  • TABLE 9 Sales Forecast, 2016 - 2022
  • TABLE 10 Sales Forecast, 2016 - 2022
  • TABLE 11 Off Patent Products in Angina Pectoris Market
  • TABLE 12 Sales Forecast, 2016 - 2022
  • TABLE 13 Sales Forecast, 2016 - 2022
  • TABLE 14 Sales Forecast, 2016 - 2022
  • TABLE 15 Off Patent Products in Angina Pectoris Market
  • TABLE 16 Sales Forecast, 2016 - 2022
  • TABLE 17 Off Patent Products in Angina Pectoris Market
  • TABLE 18 Sales Forecast, 2016 - 2022

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Age Specific Prevalence of Stable Angina Pectoris in the U.S.+ Top Five EU Markets (Germany, U.K., France, Italy, Spain)
  • FIG. 8 Age and Gender Specific Prevalence of Stable Angina Pectoris in the U.S.
  • FIG. 9 Age and Gender Specific Incidence of Stable Angina Pectoris in the U.S.
  • FIG. 10 Age and Gender Specific Prevalence of Angina Pectoris in the U.K.
  • FIG. 11 Age and Gender Specific Incidence of Angina Pectoris in the U.K.
  • FIG. 12 Age and Gender Specific Prevalence of Angina Pectoris in Japan
  • FIG. 13 Angina Pectoris Treatment Market by Therapeutic Class
  • FIG. 14 Regional Market Size, 2016 - 2022
  • FIG. 15 Market Shares Distribution, 2016 - 2022
  • FIG. 16 Sales by Therapeutic Class, 2016 - 2022
  • FIG. 17 Branded Sales by Regions, 2016 - 2022
  • FIG. 18 Angina Pectoris Sector SWOT
  • FIG. 19 Sanofi SWOT Analysis
  • FIG. 20 Gilead Sciences SWOT Analysis
  • FIG. 21 AstraZeneca SWOT Analysis
  • FIG. 22 Amgen SWOT Analysis
  • FIG. 23 GlaxoSmithKline SWOT Analysis
  • FIG. 24 Eli Lilly SWOT Analysis
  • FIG. 25 Pfizer SWOT Analysis
Back to Top